Non-Inferiority Trial Comparing Immunogenicity From 1-Dose of Bivalent HPV Vaccine in Girls to 3-Doses of Quadrivalent Vaccine in Women: The PRIMAVERA-ESCUDDO Trial
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 30 Sep 2019
Price : $35 *
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck
- Indications Anal cancer; Cervical cancer; Condylomata acuminata; Human papillomavirus infections; Vulvovaginal cancer
- Focus Pharmacodynamics
- Acronyms The PRIMAVERA-ESCUDDO Trial
- 26 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 24 Sep 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 2 Sep 2019 to 30 Sep 2019.
- 27 Aug 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 30 Aug 2019 to 2 Sep 2019.